These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 17131223)

  • 1. The natural history of Parkinson's disease.
    Poewe W
    J Neurol; 2006 Dec; 253 Suppl 7():VII2-6. PubMed ID: 17131223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical measures of progression in Parkinson's disease.
    Poewe W
    Mov Disord; 2009; 24 Suppl 2():S671-6. PubMed ID: 19877235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical progression of Parkinson's disease.
    Poewe W; Mahlknecht P
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S28-32. PubMed ID: 20123553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors of Rapid symptoms progression in patients with newly diagnosed parkinson's disease.
    Tsiouris KM; Konitsiotis S; Koutsouris DD; Fotiadis DI
    Artif Intell Med; 2020 Mar; 103():101807. PubMed ID: 32143804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Does early detection of non-motor symptoms facilitate early treatment of Parkinson's disease?].
    Hasegawa K
    Brain Nerve; 2012 Apr; 64(4):453-61. PubMed ID: 22481518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The need for neuroprotective therapies in Parkinson's disease: a clinical perspective.
    Poewe W
    Neurology; 2006 May; 66(10 Suppl 4):S2-9. PubMed ID: 16717249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The factor structure of the UPDRS as an index of disease progression in Parkinson's disease.
    Evans JR; Mason SL; Williams-Gray CH; Foltynie T; Trotter M; Barker RA
    J Parkinsons Dis; 2011; 1(1):75-82. PubMed ID: 23939258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
    Goetz CG; Stebbins GT; Blasucci LM
    Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Rating scale and functional prognosis of Parkinson's disease].
    Nakano I; Fujimoto K
    Nihon Rinsho; 2000 Oct; 58(10):2132-8. PubMed ID: 11068460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the progression of Parkinson's disease: a metabolic network approach.
    Eckert T; Tang C; Eidelberg D
    Lancet Neurol; 2007 Oct; 6(10):926-32. PubMed ID: 17884682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autonomic dysfunction according to disease progression in Parkinson's disease.
    Kim JB; Kim BJ; Koh SB; Park KW
    Parkinsonism Relat Disord; 2014 Mar; 20(3):303-7. PubMed ID: 24382402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonmotor symptoms in nursing home residents with Parkinson's disease: prevalence and effect on quality of life.
    Weerkamp NJ; Tissingh G; Poels PJ; Zuidema SU; Munneke M; Koopmans RT; Bloem BR
    J Am Geriatr Soc; 2013 Oct; 61(10):1714-21. PubMed ID: 24117286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The factor structure of the UPDRS motor scores changes during early Parkinson's disease.
    Brakedal B; Tysnes OB; Skeie GO; Larsen JP; Müller B
    Parkinsonism Relat Disord; 2014 Jun; 20(6):617-21. PubMed ID: 24685659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parkinson's disease and dementia: a longitudinal study (DEMPARK).
    Balzer-Geldsetzer M; Costa AS; Kronenbürger M; Schulz JB; Röske S; Spottke A; Wüllner U; Klockgether T; Storch A; Schneider C; Riedel O; Wittchen HU; Seifried C; Hilker R; Schmidt N; Witt K; Deuschl G; Mollenhauer B; Trenkwalder C; Liepelt-Scarfone I; Gräber-Sultan S; Berg D; Gasser T; Kalbe E; Bodden M; Oertel WH; Dodel R
    Neuroepidemiology; 2011; 37(3-4):168-76. PubMed ID: 22067139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relevance of pre-motor symptoms in Parkinson's disease.
    Visanji N; Marras C
    Expert Rev Neurother; 2015 Oct; 15(10):1205-17. PubMed ID: 26416397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting outcomes in Parkinson's disease: comparison of simple motor performance measures and The Unified Parkinson's Disease Rating Scale-III.
    Grill S; Weuve J; Weisskopf MG
    J Parkinsons Dis; 2011; 1(3):287-98. PubMed ID: 23939309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unveiling relevant non-motor Parkinson's disease severity symptoms using a machine learning approach.
    Armañanzas R; Bielza C; Chaudhuri KR; Martinez-Martin P; Larrañaga P
    Artif Intell Med; 2013 Jul; 58(3):195-202. PubMed ID: 23711400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Disease-modification" trials in Parkinson disease: target populations, endpoints and study design.
    Rascol O
    Neurology; 2009 Feb; 72(7 Suppl):S51-8. PubMed ID: 19221315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Concept of Prodromal Parkinson's Disease.
    Mahlknecht P; Seppi K; Poewe W
    J Parkinsons Dis; 2015; 5(4):681-97. PubMed ID: 26485429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.